FDA Grants Priority Review to Genentech's Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Priority Review recognises the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options1,2Additional.
StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) in a report published on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Separately, HC Wainwright decreased their target price on Minerva Neurosciences from $11.00 to $7.00 and set a neutral rating on the stock in a research report […]
/PRNewswire/ Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 2 phase III clinical trial in the.
Cellectar Biosciences and City of Hope Cancer Center Enter globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.